171 related articles for article (PubMed ID: 28032464)
1. Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors.
McIver AL; Zhang W; Liu Q; Jiang X; Stashko MA; Nichols J; Miley MJ; Norris-Drouin J; Machius M; DeRyckere D; Wood E; Graham DK; Earp HS; Kireev D; Frye SV; Wang X
ChemMedChem; 2017 Feb; 12(3):207-213. PubMed ID: 28032464
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR modeling and molecular docking study on Mer kinase inhibitors of pyridine-substituted pyrimidines.
Yu Z; Li X; Ge C; Si H; Cui L; Gao H; Duan Y; Zhai H
Mol Divers; 2015 Feb; 19(1):135-47. PubMed ID: 25355276
[TBL] [Abstract][Full Text] [Related]
3. Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group.
Zhao J; Zhang D; Zhang W; Stashko MA; DeRyckere D; Vasileiadi E; Parker RE; Hunter D; Liu Q; Zhang Y; Norris-Drouin J; Li B; Drewry DH; Kireev D; Graham DK; Earp HS; Frye SV; Wang X
J Med Chem; 2018 Nov; 61(22):10242-10254. PubMed ID: 30347155
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore-Based 3D-QSAR Modeling, Virtual Screening and Molecular Docking Analysis for the Detection of MERTK Inhibitors with Novel Scaffold.
Zhou S; Zhou L; Cui R; Tian Y; Li X; You R; Zhong L
Comb Chem High Throughput Screen; 2016; 19(1):73-96. PubMed ID: 26632441
[TBL] [Abstract][Full Text] [Related]
5. Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors.
Wang X; Liu J; Zhang W; Stashko MA; Nichols J; Miley MJ; Norris-Drouin J; Chen Z; Machius M; DeRyckere D; Wood E; Graham DK; Earp HS; Kireev D; Frye SV
ACS Med Chem Lett; 2016 Dec; 7(12):1044-1049. PubMed ID: 27994735
[TBL] [Abstract][Full Text] [Related]
6. Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors.
Zhang W; Zhang D; Stashko MA; DeRyckere D; Hunter D; Kireev D; Miley MJ; Cummings C; Lee M; Norris-Drouin J; Stewart WM; Sather S; Zhou Y; Kirkpatrick G; Machius M; Janzen WP; Earp HS; Graham DK; Frye SV; Wang X
J Med Chem; 2013 Dec; 56(23):9683-92. PubMed ID: 24195762
[TBL] [Abstract][Full Text] [Related]
7. The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase.
Gajiwala KS; Grodsky N; Bolaños B; Feng J; Ferre R; Timofeevski S; Xu M; Murray BW; Johnson TW; Stewart A
J Biol Chem; 2017 Sep; 292(38):15705-15716. PubMed ID: 28724631
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors.
Inoue S; Yamane Y; Tsukamoto S; Murai N; Azuma H; Nagao S; Nishibata K; Fukushima S; Ichikawa K; Nakagawa T; Hata Sugi N; Ito D; Kato Y; Goto A; Kakiuchi D; Ueno T; Matsui J; Matsushima T
Bioorg Med Chem Lett; 2021 Sep; 48():128247. PubMed ID: 34271070
[TBL] [Abstract][Full Text] [Related]
9. Discovering novel 7-azaindole-based series as potent AXL kinase inhibitors.
Feneyrolles C; Guiet L; Singer M; Van Hijfte N; Daydé-Cazals B; Fauvel B; Chevé G; Yasri A
Bioorg Med Chem Lett; 2017 Feb; 27(4):862-866. PubMed ID: 28094183
[TBL] [Abstract][Full Text] [Related]
10. Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status.
Cummings CT; Zhang W; Davies KD; Kirkpatrick GD; Zhang D; DeRyckere D; Wang X; Frye SV; Earp HS; Graham DK
Mol Cancer Ther; 2015 Sep; 14(9):2014-22. PubMed ID: 26162689
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.
Zhang W; McIver AL; Stashko MA; DeRyckere D; Branchford BR; Hunter D; Kireev D; Miley MJ; Norris-Drouin J; Stewart WM; Lee M; Sather S; Zhou Y; Di Paola JA; Machius M; Janzen WP; Earp HS; Graham DK; Frye SV; Wang X
J Med Chem; 2013 Dec; 56(23):9693-700. PubMed ID: 24219778
[TBL] [Abstract][Full Text] [Related]
12. Identification and SAR of a new series of thieno[3,2-d]pyrimidines as Tpl2 kinase inhibitors.
Ni Y; Gopalsamy A; Cole D; Hu Y; Denny R; Ipek M; Liu J; Lee J; Hall JP; Luong M; Telliez JB; Lin LL
Bioorg Med Chem Lett; 2011 Oct; 21(19):5952-6. PubMed ID: 21862328
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for selective small molecule kinase inhibition of activated c-Met.
Rickert KW; Patel SB; Allison TJ; Byrne NJ; Darke PL; Ford RE; Guerin DJ; Hall DL; Kornienko M; Lu J; Munshi SK; Reid JC; Shipman JM; Stanton EF; Wilson KJ; Young JR; Soisson SM; Lumb KJ
J Biol Chem; 2011 Apr; 286(13):11218-25. PubMed ID: 21247903
[TBL] [Abstract][Full Text] [Related]
14. MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme.
Knubel KH; Pernu BM; Sufit A; Nelson S; Pierce AM; Keating AK
Oncotarget; 2014 Mar; 5(5):1338-51. PubMed ID: 24658326
[TBL] [Abstract][Full Text] [Related]
15. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK.
Bernsmeier C; Pop OT; Singanayagam A; Triantafyllou E; Patel VC; Weston CJ; Curbishley S; Sadiq F; Vergis N; Khamri W; Bernal W; Auzinger G; Heneghan M; Ma Y; Jassem W; Heaton ND; Adams DH; Quaglia A; Thursz MR; Wendon J; Antoniades CG
Gastroenterology; 2015 Mar; 148(3):603-615.e14. PubMed ID: 25479139
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Novel Macrocyclic MERTK/AXL Dual Inhibitors.
Kong D; Tian Q; Chen Z; Zheng H; Stashko MA; Yan D; Earp HS; Frye SV; DeRyckere D; Kireev D; Graham DK; Wang X
J Med Chem; 2024 Apr; 67(7):5866-5882. PubMed ID: 38556760
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
[TBL] [Abstract][Full Text] [Related]
18. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
[TBL] [Abstract][Full Text] [Related]
19. UNC1062, a new and potent Mer inhibitor.
Liu J; Zhang W; Stashko MA; Deryckere D; Cummings CT; Hunter D; Yang C; Jayakody CN; Cheng N; Simpson C; Norris-Drouin J; Sather S; Kireev D; Janzen WP; Earp HS; Graham DK; Frye SV; Wang X
Eur J Med Chem; 2013 Jul; 65():83-93. PubMed ID: 23693152
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of close analogs of LCRF-0004, a potent and selective RON receptor tyrosine kinase inhibitor.
Raeppel SL; Raeppel F; Therrien E
Bioorg Med Chem Lett; 2015 Jun; 25(12):2527-31. PubMed ID: 25953155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]